MDC-ANG

MDC-ANG is a preclinical long-acting injectable antipsychotic candidate developed by Medincell in collaboration with Teva using Medincell's BEPO drug-delivery technology. The program was described as a formulation based on an already approved active pharmaceutical ingredient with established safety and efficacy, designed to provide controlled extended release after injection and potentially improve adherence in severe psychiatric illness such as schizophrenia, but the specific active ingredient and molecular target were not publicly disclosed. Medincell later reported that the partnered preclinical antipsychotic program MDC-ANG was discontinued for strategic reasons.